Xilio Therapeutics plans to initiate a Phase 2 trial of XTX101, its tumor-activated anti-CTLA-4 therapy, in combination with atezolizumab for microsatellite stable colorectal cancer in Q3 2024, with initial data expected by year-end.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.